High folic acid consumption leads to pseudo-MTHFR deficiency, altered lipid metabolism, and liver injury in mice

Karen E Christensen, Leonie G Mikael, Kit-Yi Leung, Nancy Lévesque, Liyuan Deng, Qing Wu, Olga V Malysheva, Ana Best, Marie A Caudill, Nicholas DE Greene, and Rima Rozen

ABSTRACT

Background: Increased consumption of folic acid is prevalent, leading to concerns about negative consequences. The effects of folic acid on the liver, the primary organ for folate metabolism, are largely unknown. Methylenetetrahydrofolate reductase (MTHFR) provides methyl donors for S-adenosylmethionine (SAM) synthesis and methylation reactions. Objective: Our goal was to investigate the impact of high folic acid intake on liver disease and methyl metabolism. Design: Folic acid–supplemented diet (FASD, 10-fold higher than recommended) and control diet were fed to male +/+ and +/+ mice for 6 mo to assess gene-nutrient interactions. Liver pathology, folate and choline metabolites, and gene expression in folate and lipid pathways were examined. Results: Liver and spleen weights were higher and hematologic profiles were altered in FASD-fed mice. Liver histology revealed unusually large, degenerating cells in FASD +/– mice, consistent with non-alcoholic fatty liver disease. High folic acid inhibited MTHFR activity in vitro, and MTHFR protein was reduced in FASD-fed mice. 5-Methyltetrahydrofolate, SAM, and SAM/S-adenosylhomocysteine ratios were lower in FASD and MTHFR–/– livers. Choline metabolites, including phosphatidylcholine, were reduced due to genotype and/or diet in an attempt to restore methylation capacity through choline/betaine-dependent SAM synthesis. Expression changes in genes of one-carbon and lipid metabolism were particularly significant in FASD +/– mice. The latter changes, which included higher nuclear sterol regulatory element-binding protein 1, higher Sreb2 messenger RNA (mRNA), lower farnesoid X receptor (Nr1b4) mRNA, and lower Cyp7a1 mRNA, would lead to greater lipogenesis and reduced cholesterol catabolism into bile. Conclusions: We suggest that high folic acid consumption reduces MTHFR protein and activity levels, creating a pseudo-MTHFR deficiency. This deficiency results in hepatocyte degeneration, suggesting a 2-hit mechanism whereby mutant hepatocytes cannot accommodate the lipid disturbances and altered membrane integrity arising from changes in phospholipid/lipid metabolism. These preliminary findings may have clinical implications for individuals consuming high-dose folic acid supplements, particularly those who are MTHFR deficient. Am J Clin Nutr 2015;101:646–58.

Keywords choline metabolism, folic acid, lipid metabolism, liver, methylenetetrahydrofolate reductase

INTRODUCTION

Folates are required for nucleotide synthesis and S-adenosylmethionine (SAM)–dependent methylation reactions (Supplemental Figure 1). Folic acid is a synthetic folate added to fortified foods and nutritional supplements. Fortification has reduced the incidence of neural tube defects (1, 2) and other disorders (3), but there are concerns that high folic acid intake, due to fortification and vitamin supplementation, may negatively affect health (4, 5). Recent National Health and Nutrition Examination Survey data showed that ~25% of children and 5% of adults older than 50 y consume more than the recommended upper limit for folic acid (6–8). Unmetabolized folic acid (UFA) appears in plasma after consuming.

1 From the Departments of Human Genetics and Pediatrics, McGill University, and the Montreal Children’s Hospital site of the McGill University Health Centre Research Institute, Montreal, Quebec, Canada (KEC, LGM, NL, LD, QW, and RR); Developmental Biology and Cancer Programme, Institute of Child Health, University College London, London, United Kingdom (K-YL and NDEG); the Division of Nutritional Sciences and Genomics, Cornell University, Ithaca, NY (OVM and MAC); and the Department of Mathematics and Statistics, McGill University, Montreal, Quebec, Canada (AB).

2 Supported by grant MOP-43232 (RR) from the Canadian Institutes of Health Research and grant 8003794 (NDEG) from the UK Medical Research Council. This is an open access article distributed under the CC-BY license (http://creativecommons.org/licenses/by/3.0/).

3 Supplemental Figure 1 and Supplemental Tables 1 and 2 are available from the “Supplemental data” link in the online posting of the article and from the same link in the online table of contents at http://ajcn.nutrition.org.

4 KEC and LGM contributed equally to this work.

5 Address correspondence to R Rozen, McGill University, Montreal Children’s Hospital, 4060 Ste Catherine West, Room 200, Montreal, Quebec, Canada, H3Z 2Z3. E-mail: rima.rozen@mcgill.ca.

6 Abbreviations used: Actb, β-actin; ATGL, adipose triglyceride lipase; Bdh, BCL2-antagonist/killer 1; Bcxl, Bcl-2-like 1; Bhmt, betaine-homocysteine methyltransferase; B2m, β-2-microglobulin; CD, control diet; Chdh, choline dehydrogenase; Cyp7a1, cytochrome P450, family 7, subfamily a, polypeptide 1; Fads2, fatty acid desaturase 2; FASD, folic acid–supplemented diet; FXR, farnesoid X receptor; LysoPtdCho, lysosphatidylcholine; Mat1a, methionine adenosyltransferase I α; mRNA, messenger RNA; MTHFR, methylenetetrahydrofolate reductase; Mtr, methionine synthase; NADF, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; Nr1b4, nuclear receptor subfamily 1, group H, member 4; Ova, ovotransferrin; PCho, phosphocholine; PE, phosphatidylethanolamine; PEMT, phosphatidylethanolamine N-methyltransferase; Ppap2a, patatin-like phospholipase domain containing 2; PPARα, peroxisome proliferator-activated receptor α; PdcdCho, phosphodiplaceinholine; RBC, red blood cell; RDA, Recommended Dietary Allowance; RT-PCR, reverse transcriptase-polymerase chain reaction; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; Scd1, stearoyl-coenzyme A desaturase 1; Silha, succinate dehydrogenase; SM, sphingomyelin; SREBP, sterol regulatory element-binding protein; THF, tetrahydrofolate; UFA, unmetabolized folic acid; Ywhaz, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide.
the recommended daily intake of 400 μg/d (9). However, most supplements contain ≥400 μg, and supplement users in the Framingham cohort were 2.3-fold more likely to have high circulating UFA than nonusers (10). Supplements containing 4000–5000 μg/d are recommended to women with high-risk pregnancies (11, 12). In an elderly population administered 5000 μg/d for 3 wk, UFA was found in 100% of the study group (compared with 26% at baseline), and concentrations rose from 0.8% to 15% of total folates (13).

The possible negative effects of high folic acid consumption have prompted investigations into its impact on health. We found that pregnancy losses and embryonic heart defects were more common in mice consuming a diet high in folic acid (14). Other researchers have suggested links between circulating UFA and lower cognitive test scores (15), as well as impaired immune function (16) in humans.

The liver is an important organ in folate metabolism; most folate-dependent enzymes and the majority of folate are found there (17). Nonetheless, the effect of high folic acid consumption on the liver has not been well examined. UFA may affect the liver through mechanisms such as enzyme inhibition, either directly (18–23) or through its metabolites (24–26). The impact of UFA may be modulated by genetic variants in these enzymes.

Methylenetetrahydrofolate reductase (MTHFR) produces methyltetrahydrofolate for remethylation of homocysteine to methionine by methionine synthase (Supplemental Figure 1). In the liver and kidney, an alternate pathway uses betaine to methylate homocysteine through betaine-homocysteine methyltransferase (27) linking choline metabolism to folate metabolism. We observed increased flux through betaine-homocysteine methyltransferase when folate metabolism was disturbed in humans (28, 29) and mice (28, 30) due to MTHFR mutation (28) or low dietary folate (30). We found that male mice relied more on the betaine pathway than did female mice, resulting in greater susceptibility to hepatic steatosis (30).

In this report, we examine the effects of high folic acid consumption on the liver. To investigate diet and gene variant interactions, we used mice with mild MTHFR deficiency, a model for the MTHFR 677 C>T polymorphism, the most studied variant in folate metabolism with 5–20% homozygosity (31).

METHODS

Mice, diets, and sample collection

All experiments were performed within the guidelines of the Canadian Council on Animal Care and approved by the Animal Care Committee of the Research Institute of the McGill University Health Centre. BALB/c Mthfr+/+ and Mthfr−/− males (32) were placed on control (CD) and 10× folic acid–supplemented (FASD) amino acid–defined diets (Harlan) at weaning. CD (TD.01369) contained 2 mg/kg folic acid, the Recommended Dietary Allowance (RDA) for rodents set by the American Institute of Nutrition (33), whereas FASD (TD.09258) contained 20 mg/kg diet (10× RDA); both diets contained 2.5 g/kg choline bitartrate, 3.3 g/kg L-methionine, and 1% succinylsulfathiazole (to inhibit folate production by intestinal flora). Litters were randomly assigned to CD or FASD to produce a total of 7–8 mice in each of the 4 diet/genotype experimental groups (29 total). Mice were housed under specific pathogen-free conditions in a controlled environment (12 h/12 h light/dark cycle, 18–24°C) with ad libitum access to food and water.

After 6 mo on diets, mice were sacrificed in random order by CO2 asphyxiation and body weights recorded. Blood was collected by cardiac puncture in potassium-EDTA–coated tubes. Complete blood counts were performed at the Animal Resource Center, McGill University. Plasma was obtained by centrifugation at 3000 × g for 7 min and stored at −75°C or below. Tissues were collected, weighed, and rinsed with cold phosphate-buffered saline. The entire left lobe of the liver was fixed in 4% paraformaldehyde for 1 d and stored at 4°C in 70% ethanol; the remaining tissue was snap frozen on dry ice and stored at −75°C or below.

Histologic examination

Fixed liver was embedded in paraffin and cut in 5-μm sections. Sections were stained with hematoxylin and eosin or Masson’s trichrome stain (Polysciences Inc.). Two hematoxylin and eosin–stained sections per mouse were examined in random order at 100×, 200×, and 400× magnification (2 fields per section) and scored for the presence of degenerating cells and lipid droplets by a blinded observer and confirmed by a second observer. Degenerating cells were enlarged, contained strands of eosinophilic material, and had clearing of the cytoplasm. Preliminary inspection showed that the liver sections fell into 2 groups: 1) no or small localized foci of degenerating cells or 2) large numbers of degenerating cells affecting at least half of the section. Therefore, livers were scored as containing degenerating cells if more than half of the hepatocytes in the field at 200× were affected in at least 3 of the 4 fields examined (i.e., small localized foci were not considered meaningful). Accumulation of lipid droplets (microvesicular and macrovesicular) was graded as described (30).

MTHFR inhibition assays

Brain and liver extracts for enzyme assays were prepared from ~50 mg frozen tissue under native conditions [lysis buffer: 50 mmol/L potassium phosphate, 0.3 mmol/L EDTA, supplemented with protease (Roche) and phosphatase inhibitors (Thermo Scientific)] by using a bead mill and cleared by centrifugation. Protein concentration was determined by Bradford assay using bovine serum albumin as a standard. Activity assays were performed as in Goyette et al. (34) with the following modifications: the assay mix was modified to contain 200 μmol/L substrate and 30 μmol/L flavin adenine dinucleotide. Then, 1.4 mmol/L folic acid in 3.5 mmol/L NaOH was added to the assay to final concentrations of 0, 250, 500, and 750 μmol/L, and 3.5 mmol/L NaOH was added to each reaction to equalize the final concentration of NaOH in each reaction. Assays were performed in triplicate. Results are expressed as percent MTHFR activity at 0 μmol/L folic acid and reported as the mean ± SEM of 2 (brain) or 3 (liver) separate experiments.

Western blotting

Total liver extracts were prepared as for MTHFR assays (see previous paragraph). Nuclear and cytoplasmic fractions were isolated by using the NE-PER Nuclear Protein Extraction Kit (Thermo Scientific) following the manufacturer’s instructions.
Protein concentration was determined by Bradford assay by using bovine serum albumin as a standard. Western blotting was performed with conventional methods by using 25 μg total or cytoplasmic protein or 15 μg nuclear protein. Primary antibodies were sterol regulatory element-binding protein (SREBP-1; Santa Cruz Biotechnology), cyclic AMP-responsive element-binding protein (Cell Signaling Technology), β-actin (Sigma-Aldrich), and MTHFR (35). Secondary antibody was horseradish peroxidase–coupled anti–rabbit IgG (GE Healthcare). Bands were visualized with Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare) and film exposure and quantified by densitometry by using Quantity One 1-D Analysis Software version 4.6.9 (Bio-Rad). Results were normalized to the β-actin loading control and reported relative to the mean value for CD-fed Mthfr<sup>−/−</sup> mice, which was standardized to a reference value of 1.

Alkaline phosphatase treatment

Alkaline phosphatase treatment of protein extracts was adapted from Yamada et al. (36). Briefly, total liver extract was isolated in RIPA lysis buffer (denaturing conditions: 150 mmol/L NaCl, 50 mmol/L Tris-HCl, 1 mmol/L EDTA, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with protease inhibitors. Then, 50 μg protein was treated with 25 units of calf intestinal alkaline phosphatase (Roche), incubated at 37°C for 1 h, and analyzed for MTHFR by Western blotting.

Folates

The distribution of folates in frozen liver [specifically: folic acid, dihydrofolate, tetrahydrofolate (THF), methenylTHF, methyleneTHF, methylTHF, and formylTHF] was determined by liquid chromatography–electrospray ionization tandem mass spectrometry. Samples were prepared as described in Christensen et al. (37). Analytes were resolved by reversed-phase chromatography and measured as described previously (37–39). Total folates are reported as nmol/g liver; the concentration of individual folate forms was normalized to total folate concentration and reported as the percentage of total folates to allow comparison of distributions.

Choline metabolites

The concentrations of choline metabolites in frozen liver were measured by liquid chromatography–mass spectrometry. Choline, betaine, glycerophosphocholine, phosphocholine (PCho), phosphatidylcholine (PtdCho), sphingomyelin (SM), and lysophosphatidylcholine (LysOPtdCho) were measured by using the method in Koc et al. (40), with modifications (29, 41). SAM and S-adenosylhomocysteine (SAH) were determined by liquid chromatography–mass spectrometry as described (42), with modifications based on our instrumentation (43).

Quantitative reverse transcriptase–polymerase chain reaction

Total RNA was extracted from ~10 mg frozen liver by using the RNeasy Mini kit with on-column DNase I treatment (Qiagen). Complementary DNA synthesis was performed as in Knock et al. (44). Quantitative reverse transcriptase–polymerase chain reaction (RT-PCR) was performed by using Platinum SYBR Green qPCR SuperMix-UDG master mix (Invitrogen) on a Lightcycler LC480 (Roche Diagnostics). The following reference genes were evaluated: β-actin (Actb), β-2-microglobulin (B2m), succinate dehydrogenase (Sdha), and tyrosine 3-monoxygenase/tryptophan 5-monoxygenase activation protein, zeta polypeptide (Ywhaz) [all primers as in Christensen et al. (30)] and glyceraldehyde-3-phosphate dehydrogenase (Gapdh) [primers as in Leclerc et al. (45)]. The 3 most stably expressed reference genes were determined (Gapdh, Actb, and B2m) and used to calculate one normalization factor for target gene expression by geNorm v.3.4 (Ghent University Hospital Center for Medical Genetics) (46). Primers for the target genes betaine-homocysteine methyltransferase (Bhmt) and methionine synthase (Mtr) were reported in Christensen et al. (30). Primers for Bcl2-like 1 (Bcl-XL) and BCL2-antagonist/killer 1 (Bak) were reported in Garcia-Crespo et al. (47). All other target gene primers [choline dehydrogenase (Chdh); cytochrome P450, family 7, subfamily a, polypeptide 1 (Cyp7a1); fatty acid desaturase 2 (Fads2); methionine adenosyltransferase I, α (Matla); nuclear receptor subfamily 1, group H, member 4 (Nrlh4); farnesoid X receptor (FXR); phosphatidylethanolamine N-methyltransferase (Pemt); patatin-like phospholipase domain containing 2 (Pnp2); peroxisome proliferator-activated receptor α (Ppara); stearyl-coenzyme A desaturation 1 (Scd1); sterol regulatory element-binding transcription factor 1 (Srebp1); and sterol regulatory element-binding transcription factor 2 (Srebp2)] were designed by using Primer-BLAST (National Center for Biotechnology Information) (48). For a complete list of primer sequences and reaction conditions, see Supplemental Table 1.

Quantitative CpG methylation analysis

Using a panoply of analysis tools, CpG islands or similar features could not be identified in the Cyp7a1 gene or its vicinity (data not shown). However, 2 CpG sites in the Cyp7a1 gene were identified as potentially differentially methylated because of a DNA region reported to contain methylation flags (49) and were assessed by bisulfite pyrosequencing as previously described (45). Briefly, extracted DNA was subjected to bisulfite treatment by using the Epitect Bisulfite Kit (Qiagen). Primers for pyrosequencing of Cyp71a were designed with PyroMark Assay Design 2.0 software (Qiagen) (5′-biotinylated oligonucleotide: 5′-ACCTCCTCCA-TATCATCAAAAAATAAAAAAT-3′, sense PCR primer: 5′-AATTTGGGAAAAAGTGGTTGAGAG-3′, sequencing primer: 5′-GAATTTGTATATAGGGGATTAG-3′). Pyrosequencing was performed on the PyroMark Q24 Platform (Qiagen). Data were interpreted with PyroMark Q24 2.0.6 analysis software.

Caspase 3/7 activity

Total liver extracts were prepared as for MTHFR assays (see above). Caspase activity was measured with the Caspase-Glo 3/7 Assay System (Promega) by using 2 μg total liver extract in 50 μL assay reagent following the manufacturer’s instructions. Luminescence was measured with a Glo-max Multi Detection Microplate reader (Promega).

Statistical methods

All results are expressed as mean ± SE. Because this preliminary study involved the use of a new diet, with unpredictable effects, we did not perform a sample size calculation. Sample sizes were determined based on previous experience with these
methods in our mouse models (30, 37). Unless noted, data were analyzed by using 2-factor ANOVA with diet and genotype as the independent variables, followed by post hoc analysis by Tukey to correct for multiple comparisons if the interaction term was significant or borderline significant ($P \leq 0.058$ where indicated).

Effect of folic acid on MTHFR activity was assessed by using 1-factor ANOVA for comparison with the 0-mu mol/L folic acid control, with post hoc analysis by Tukey. Incidence of degenerating hepatocytes was assessed by exact binary logistic regression for diet and genotype with individual mice as the unit of analysis by using SAS version 9.4 (SAS Institute). Statistical outliers were identified by using Grubb’s test (QuickCalc; GraphPad Software) and removed from the analysis. No other corrections were made for multiple testing. Results of statistical tests were considered significant at $P \leq 0.05$ and borderline significant up to $P \leq 0.075$ where indicated. Statistical analyses were carried out by using SPSS version 20.0.0 (SPSS Inc.) unless noted.

RESULTS

FASD consumption affects organ weights and hematology

Liver and spleen weights (adjusted for body weight) of mice fed FASD were significantly higher than those of mice fed CD (Table 1). These particular organs may be sensitive to folate intake due to their roles in folate metabolism and hematopoiesis. White blood cell counts (specifically lymphocytes) were significantly higher in Mthfr<sup>−/−</sup> mice compared with Mthfr<sup>+/+</sup>, but this difference was not affected by diet (Table 2). In contrast, red blood cell (RBC) counts and related hematologic parameters were significantly affected by both diet and Mthfr genotype, with more marked changes in the FASD-fed Mthfr<sup>−/−</sup> group (Table 2). The reduction in RBC counts, hematocrit, and hemoglobin because of FASD and genotype and the larger mean corpuscular volume because of FASD are reminiscent of the megaloblastic anemia associated with folate deficiency.

Liver histologic examination reveals that the combination of MTHFR deficiency and high folic acid consumption causes liver injury

Examination of hematoxylin and eosin–stained sections revealed histologic changes associated with nonalcoholic fatty liver disease (NAFLD). Considerable numbers of unusually large cells with vacuolation of the cytoplasm, consistent with hydropic degeneration or hepatocyte ballooning, were observed (Figure 1). Both diet and genotype significantly affected the incidence of degenerating cells. However, it is clear from inspection of the data (Figure 1C) that these results are driven by

### Table 1

| Characteristic               | CD        | FASD      | 2-Factor ANOVA $P$ value |
|-----------------------------|-----------|-----------|-------------------------|
|                             | Mthfr<sup>+/+</sup> | Mthfr<sup>−/−</sup> | Genotype | Diet | Interaction |
| Body weight, g              | 29.8 ± 1.2 | 28.2 ± 1.2 | 28.6 ± 0.9 | 29.7 ± 1.2 | 0.831 | 0.897 | 0.224 |
| Liver (as % body weight)    | 0.04 ± 0.20 | 0.40 ± 0.23 | 0.43 ± 0.16 | 0.49 ± 0.07 | 0.118 | 0.001 | 0.105 |
| Spleen                      | 0.28 ± 0.01 | 0.31 ± 0.02 | 0.34 ± 0.03 | 0.36 ± 0.04 | 0.389 | 0.046 | 0.970 |
| Brain                       | 1.54 ± 0.07 | 1.58 ± 0.04 | 1.58 ± 0.04 | 1.47 ± 0.02 | 0.451 | 0.469 | 0.128 |

Note: $n = 6–8$ per group. CD, control diet; FASD, folic acid–supplemented diet.

<sup>1</sup>Mean ± SE (analyzed by 2-factor ANOVA; all such values).
the FASD Mthfr+/-- group, as 6 of 7 of FASD Mthfr+/-- livers presented with this phenotype, compared with a maximum of 1 of 7 in the other groups. Hydropic degeneration, caused by accumulation of fluid in the cytoplasm, is associated with disturbed membrane integrity (50). Changes in membrane integrity can result from disruption of phospholipid metabolism, because phospholipids, especially phosphatidylcholine (PdCho), are critical components of membranes (51).

Lipid droplets were also observed, as previously reported in Mthfr+/-- mice and in mice fed control or low-folate diets (30, 52). The incidence and degree of steatosis in CD-fed mice was consistent with our previous observations of mice fed CD for 12 mo (30). The accumulation of lipids did not appear to be different between the CD+/+, CD+/-, and FASD+/+ groups (data not shown). Accurate evaluation of lipid droplet accumulation was extremely difficult for livers with large numbers of degenerated cells; therefore, the extent of steatosis in FASD+/+ mice could not be determined. It is possible that lipid accumulation is a precursor to degeneration; additional experimentation would be required to assess. Masson’s trichrome-stained sections were also examined; no unusual collagen staining was observed (data not shown), indicating that liver damage in these mice had not yet progressed to fibrosis.

**MTHFR activity is inhibited by folic acid in vitro, and immunoreactive protein levels are reduced in FASD-fed mice**

Folic acid has previously been reported to inhibit MTHFR activity in crude brain extract (21). Because our extraction and assay methods differed from that report, we assessed the inhibition of MTHFR by folic acid in crude brain extract (Figure 2A). MTHFR was also inhibited in crude liver extract (Figure 2B). Half-maximal inhibition of MTHFR was observed at 750 μmol/L folic acid (<4-fold substrate concentration), suggesting that UFA could contribute to MTHFR deficiency.

Total immunoreactive MTHFR protein was reduced in Mthfr+/-- livers as expected. However, MTHFR protein was also affected by FASD (Figure 2C,E). The upper band in Figure 2C was identified as the phosphorylated 70-kDa isoform of MTHFR (36) by treatment with alkaline phosphatase (Figure 2D). The relative proportion of phosphorylated and nonphosphorylated MTHFR was sensitive to both diet and MTHFR deficiency (Figure 2C,F). The percentage of phosphorylated MTHFR, which is less active than the nonphosphorylated form (36), rose significantly in FASD+/+ compared with CD+/+. Overall, the immunoblotting data suggest that MTHFR activity was reduced in the liver of FASD-fed mice through reduced protein levels and greater phosphorylation.

**Methylation capacity is reduced in the livers of FASD-fed mice**

Key folate derivatives were evaluated in the liver (Figure 3 and Supplemental Table 2). There was no significant change in the concentration of total folate due to diet or genotype (Figure 3A), as previously observed in mice fed folate-supplemented diets (53). Therefore, to compare folate distributions, individual concentrations were normalized to the total and expressed as percent total folates. Folic acid in the liver was ~60% greater in mice fed FASD (Figure 3B). MethylTHF was lower in all groups compared with CD+/+ (Figure 3C), consistent with reduced expression and activity of MTHFR (Figure 2). There were no significant changes due to diet or genotype in the proportion of other folates (dihydrofolate, THF, methenylTHF, methyleneTHF, and formylTHF) (Supplemental Table 2). These findings suggest that the substrate of MTHFR, methyleneTHF, is being redistributed among the other nonmethyl forms. High folic acid intake appears to be altering methylation potential, without dramatically changing the availability of folate substrates for nucleotide synthesis and other functions. However, some variability between mice in the levels of non-methylTHF may have contributed to this lack of significance.

The concentration of SAM is affected in the same manner as methylTHF (Figure 3D), demonstrating that reduced MTHFR activity affects the supply of methionine for SAM synthesis. The concentration of SAH did not change due to either diet or genotype alone, although the interaction between those variables was significant (Figure 3E), suggesting that an effect of FASD on SAH levels is genotype dependent. It was not possible to resolve this interaction due to lack of statistical power. However, the more critical indicator of methylation capacity, the SAM/SAH ratio (Figure 3F), was lower in all groups relative to CD+/+. The graphs in Figures 2E, 3C, 3D, and 3F have very similar patterns,

![FIGURE 1](image_url) High folic acid consumption in Mthfr+/-- mice may cause degeneration of hepatocytes. Hematoxylin and eosin-stained liver sections from (A) CD+/+ and (B) FASD+/+ mice (400× magnification). Most cells in FASD Mthfr+/-- liver appear unusually large with clear patches in the cytoplasm consistent with hepatocyte degeneration. In contrast, most cells of the other 3 groups appeared normal or had only isolated abnormal cells. Examples of these unusual cells are indicated by arrows. (C) Incidence of widespread degenerating hepatocytes in diet/genotype groups (n = 7–8 per group). Both diet (P = 0.016; estimated OR: 25.0) and genotype (P = 0.009; estimated OR: 28.9) had significant effects on the incidence of widespread degeneration (exact binary logistic regression). CD, control diet; FASD, folic acid–supplemented diet.
consistent with reduced MTHFR protein leading to impaired methylTHF production with consequent reduction of SAM and SAM/SAH ratios.

Expression of methylation cycle genes is altered in FASD-fed mice

The expression of some critical genes in methylation—Mtr, Bhmt, Chdh, Mat1a, and Pemt (pathways in Supplemental Figure 1)—was evaluated by quantitative RT-PCR. These genes code for enzymes required for the supply and use of SAM in liver. Mtr and Bhmt catalyze the methylTHF-dependent and betaine-dependent remethylation of homocysteine to methionine, respectively. CHDH catalyzes the first, committed step in the metabolism of choline to betaine. MAT1A synthesizes SAM from methionine and ATP, whereas PEMT produces PtdCho from phosphatidylethanolamine (PE), consuming 3 molecules of SAM. The expression of Mtr, Chdh, and Pemt was significantly reduced in FASD-fed mice; Mat1a expression tended to be lower (P = 0.076), and Bhmt expression did not change (Figure 4). Reduced Mtr was previously reported in the livers of mice fed a folate-deficient diet (30) and suggests a shift toward folate-independent homocysteine remethylation due to reduced methylTHF substrate. A similar feedback mechanism could be lowering the expression of Pemt as a result of reduced SAM.

Choline and phospholipid metabolite concentrations are changed in Mthfr-deficient mice, particularly when fed FASD

Hepatic concentrations of choline and related metabolites were measured (Figure 5 and Supplemental Table 2). The concentration of choline did not change significantly, consistent with previous observations that choline stores in liver resist depletion (30, 54, 55). Betaine concentrations, on the other hand, dropped significantly as a result of FASD in Mthfr+/− mice, suggesting greater use of betaine for homocysteine remethylation when methylTHF abundance is reduced. Concentrations of PCho, a choline storage form and intermediate in the cytidine-diphosphocholine (CDP) choline pathway for PtdCho synthesis, were also significantly lower due to the Mthfr+/− genotype, as were the concentrations of PtdCho and its catabolite SM, with borderline significance for another catabolite, LysoPtdCho (P = 0.057). These observations suggest that there is greater reliance...
on choline metabolism to support the methylation cycle when MTHFR is deficient.

Expression of genes in lipid and cholesterol metabolism is altered by high folic acid consumption, particularly in Mthfr-deficient mice

The expression of several important genes/proteins in cholesterol and lipid metabolism was evaluated (Figure 6). Many of these genes have been shown to be involved in NAFLD (56–59). Sterol regulatory element-binding protein (SREBP) 1 and 2 are important transcriptional regulators of genes in lipogenesis and cholesterol biosynthesis, respectively, although there is overlap between the pathways. FXR (Nr1h4) is a master regulator that influences the expression of genes involved in bile acid (cholesterol), lipid, and glucose metabolism (60). SREBP-1 activity is downregulated by FXR. Peroxisome proliferator-activated receptor α (PPARα) is a transcription factor in lipid metabolism that is induced by FXR (60). CYP7A1 is an FXR target that catalyzes the first and rate-limiting step in bile acid synthesis, which is a major consumer of cholesterol. SCD1 and FADS2 are lipogenic enzymes that are targets of PPARα. Adipose triglyceride lipase (ATGL; Pnpla2) catalyzes the first, rate-limiting step in hydrolysis of triglycerides to free fatty acids, which is required to metabolize triglycerides in lipid droplets and prevent excess lipid accumulation (57).

In FASD-fed mice, the amount of the mature SREBP-1 protein was significantly higher in the nucleus and lower in the cytoplasm (Figure 6A), indicating the activation of the SREBP-1 signaling pathway (61). The expression of Srebp1 messenger RNA (mRNA) was not affected by diet or genotype (data not shown). Expression of Srebp2 (Figure 6B) was higher in FASD, particularly in Mthfr+/2 mice, suggesting that this pathway is also activated.

Expression of Nr1h4 (FXR, Figure 6C) was reduced in FASD-fed mice. An important target of FXR, Cyp7a1, was also reduced in expression in a significant manner for both diet and MTHFR deficiency (Figure 6D). Diminished expression of Nr1h4 in FASD is consistent with the reduced expression of its target Ppara (Figure 6E) and the Ppara targets Scd1 (Figure 6F) and Fads2 (Figure 6G) in FASD-fed mice. Expression of Pnpla2 (ATGL, Figure 6H) was also lower due to FASD. For 2 of the genes in lipid and cholesterol metabolism that were altered in expression due to diet, there was also an effect of genotype (Cyp7a1 and Srebp2). These findings suggest that genotype and diet may have a cumulative effect on lipid gene expression that contributes to liver injury in FASD+/2 mice.

Methylation of 2 CpG sites in the Cyp7a1 gene was higher in Mthfr-deficient mice

Because CYP7A1 is a critical protein in cholesterol export and its expression was dramatically reduced by diet and genotype, we assessed a potential mechanism for the altered expression. The methylation of 2 CpGs in the Cyp7a1 gene was examined by bisulfite pyrosequencing (n = 6/group). Methylation was higher
in \textit{Mthfr}^{-/-} compared with \textit{Mthfr}^{+/+} mice by a small but significant amount; there were no differences due to diet. CpG1 methylation rose from \sim70\% to \sim73\% (ANOVA, genotype, \(P = 0.017\)); CpG2 rose from \sim50\% to \sim53\% (ANOVA, genotype, \(P = 0.009\)). Although the observed changes were small, they may have contributed to the observed reduction in \textit{Cyp7a1} expression.

High folic acid consumption results in a proapoptotic environment in liver

The cytoplasmic clearing observed in FASD \textit{Mthfr}^{-/-} livers may be the result of cells beginning the process of apoptosis. Therefore, measurements of \textit{Bcl-XL} (antiapoptotic) and \textit{Bak} (proapoptotic) mRNA and caspase 3/7 activity were performed (Table 3). Expression of \textit{Bcl-XL} was significantly lower in FASD-fed mice (ANOVA, diet, \(P < 0.05\)), whereas \textit{Bak} expression was higher but not significantly. The \textit{Bcl-XL}/\textit{Bak} ratio, a marker of apoptotic potential (47, 62), declined significantly (Table 3), indicating a relatively proapoptotic environment compared with CD-fed mice. Caspase 3/7 activity also tended to be higher in FASD-fed mice (ANOVA, \(P = 0.064\), Table 3). Since caspase-3 can cleave SREBP3 to the mature active protein (63), our finding of higher nuclear SREBP-1 is consistent with higher caspase activity.

DISCUSSION

Concerns have been raised that excess folic acid intake may have unknown consequences (4, 5). We examined the effects of a high folic acid diet on livers of \textit{Mthfr}-deficient mice as a model for the high folate intake in many populations due to the combination of fortification and vitamin supplementation. We have previously reported that plasma folate of mice fed this 10× RDA diet is \sim2.5-fold higher than that of mice fed the RDA (14). Plasma folate was also \sim2.5-fold higher in women given 4 mg folic acid/d (10× RDA) compared with 400 mg/d (RDA) (64). A similar increase in plasma folate was observed in the US population post-1998 due to fortified foods and vitamin supplements (65). Although plasma folate increased in FASD-fed mice, plasma homocysteine did not decrease (14), as observed in human studies (64), suggesting that not all of the ingested folic acid is metabolized.

In this study, diet and \textit{Mthfr} genotype had significant effects on hematologic parameters. The lower RBC count, hematocrit, and hemoglobin and the higher mean corpuscular volume, particularly in FASD \textit{Mthfr}^{-/-} mice, are consistent with reduced hematopoiesis, suggesting that FASD may impair nucleotide biosynthesis in addition to methylation reactions.

We observed cumulative effects of \textit{Mthfr} genotype and FASD resulting in pseudo-MTHFR deficiency and reduced methylation capacity. MTHFR protein levels were lowered by the \textit{Mthfr}^{-/-} genotype, as expected, and by FASD. The proportion of phosphorylated MTHFR, which is less active (36), was higher in FASD-fed mice. Although we confirmed that MTHFR activity is inhibited by folic acid in vitro, suggesting that UFA might inhibit MTHFR in tissues, UFA in the liver was low and unlikely to have as great an effect as the expression and phosphorylation changes. Reduced methylTHF, SAM, and SAM/SAH ratio are
consequences of lower MTHFR expression and follow the same diet/genotype pattern (Figure 3). Altered methylation cycle gene expression (Figure 4) adds to the lower methylation capacity of FASD mice.

Mthfr<sup>+</sup>/<sup>–</sup> mice are particularly dependent on betaine-dependent homocysteine remethylation (28), consistent with the reduced betaine concentration in this study. However, the increased flux through betaine was insufficient to maintain SAM concentrations. Reduced Chdh expression suggests that capacity for betaine synthesis may not have met betaine demand. Altered Chdh expression may be a mechanism to spare choline for PtdCho synthesis via the CDP-choline pathway because PEMT expression is reduced. This is consistent with observations in humans as the rate of homocysteine remethylation may be reduced in patients with nonalcoholic steatohepatitis (NASH) (66).

A major consumer of liver SAM is methylation of PE to PtdCho by PEMT (51). PtdCho synthesis via the CDP-choline pathway may be upregulated to compensate for reduced SAM concentration and Pemt expression, consistent with the reduction in PCho. Lower concentrations of PCho, PtdCho, SM, and LysoPtdCho in Mthfr<sup>+</sup>/<sup>–</sup> mice suggest that reduced methylation capacity due to MTHFR deficiency leads to greater use of betaine as a one-carbon donor and affects the choline-dependent synthesis of membrane phospholipids.

PtdCho is an important component of the plasma membrane and VLDL. Reduced PtdCho synthesis can result in liver injury through at least 2 mechanisms. Altered PtdCho synthesis is associated with lipid accumulation caused by impaired secretion of lipid via VLDL particles (51, 67). VLDL particles and lipid secretion are abnormal in Mat1a<sup>–/–</sup> mice, which have reduced SAM and develop NAFLD/NASH (68).

**FIGURE 5** MTHFR deficiency alters choline and phospholipid metabolite concentrations, particularly in FASD-fed mice. The concentration of choline (A) did not change significantly. Betaine concentration (B) was significantly reduced in mice fed the FASD, and there was a significant interaction between the effects of diet and Mthfr genotype. (C) PCho was significantly lower in Mthfr<sup>–/–</sup> mice than in Mthfr<sup>+</sup>/<sup>+</sup> mice. (D) PtdCho concentrations were significantly altered by Mthfr genotype, with a significant interaction between diet and genotype. The concentrations of SM (E) and LysoPtdCho (F), products of PtdCho catabolism, were affected by Mthfr genotype. (E) SM concentrations were significantly lower in Mthfr<sup>+</sup>/<sup>–</sup> mice, and there was a borderline significant interaction between diet and genotype (P = 0.053). (F) LysoPtdCho tended to be lower in Mthfr<sup>+</sup>/<sup>–</sup> mice (P = 0.057). White bars: Mthfr<sup>+</sup>/<sup>+</sup>; gray bars: Mthfr<sup>+</sup>/<sup>–</sup>. n = 4–5 per group, mean ± SEM, analyzed by 2-factor ANOVA. Bars without a common lowercase letter are significantly different by Tukey post hoc, P < 0.05. CD, control diet; D, diet; FASD, folic acid–supplemented diet; G, genotype; LysoPtdCho, lysophosphatidylcholine; MTHFR, methylenetetrahydrofolate reductase; PCho, phosphocholine; PtdCho, phosphatidylcholine; SM, sphingomyelin.
Disrupted PtdCho synthesis may also alter membrane fluidity and integrity, which can damage hepatocytes. Reduced PtdCho/PE ratios cause membrane leakage, leading to steatohepatitis in Pemt+/− mice, and are associated with NASH in humans (69). Altered membrane integrity leads to hydropic degeneration and hepatocyte ballooning (50, 69), forms of degeneration observed in FASD Mthfr+/− livers. Reduced PtdCho and Pemt expression in FASD +/− mice may have resulted in altered membrane integrity, contributing to liver injury.
TABLE 3
FASD creates a proapoptotic environment in the liver

| Genotype Diet Interaction | Genotype | Diet | Interaction |
|---------------------------|----------|------|-------------|
|                          | CD       | FASD |             |
| Mthfr<sup>++</sup>        | 1.17 ± 0.15<sup>3</sup> | 1.23 ± 0.12 | 0.91 ± 0.06 | 0.90 ± 0.12 | 0.815 | 0.023 | 0.760 |
| Mthfr<sup>++</sup>        | 41.2 ± 5.5 | 34.3 ± 3.9 | 47.6 ± 3.0 | 47.3 ± 6.4 | 0.473 | 0.064 | 0.506 |

<sup>1</sup>n = 5–6 per group. CD, control diet; FASD, folic acid–supplemented diet.
<sup>2</sup>Relative expression by quantitative reverse transcriptase–polymerase chain reaction.
<sup>3</sup>Mean ± SE (analyzed by 2-factor ANOVA; all such values).
<sup>4</sup>Activity × 1000 (relative light units).

Other major mechanisms by which liver damage arises in NAFLD/NASH are accumulation of lipids due to increased synthesis, reduced mobilization of fatty acids from lipid droplets, and cholesterol accumulation (56, 57). We evaluated a panel of genes in these pathways, including the major regulators SREBP-1, SREBP-2, and FXR (Nr1h4). Dysregulation of SREBP-1 and SREBP-2 is commonly observed in NAFLD/NASH. PtdCho is a regulator of SREBP-1 (61); the reduction in PtdCho in FASD Mthfr<sup>++</sup> mice would be expected to activate SREBP-1, which would upregulate lipogenic pathways. We observed greater SREBP-1 in the nucleus and greater SREBP-2 mRNA associated with FASD. FXR is a bile acid receptor that regulates genes involved in the production of bile acid from cholesterol. FXR activity, which is inversely related to severity of steatosis in patients with NAFLD (60), downregulates Srebp1 and, indirectly, Cyp7a1 (56, 60). Reduced Nr1h4 in FASD-fed mice may have led to greater nuclear SREBP-1. FXR has also been shown to upregulate Ppara (60, 70). Reduced expression of Ppara and its targets Scd1 and Fads2 is consistent with lower Nr1h4 expression. Expression of Pnpla2 (ATGL) was also lower in FASD-fed mice. ATGL catalyzes the first step of triglyceride hydrolysis to generate free fatty acids; triglyceride hydrolysis products upregulate PPARα signaling (71). Disruption of Pnpla2 prevents extraction of free fatty acids from lipid droplets, leading to severe steatosis and hepatic inflammation in mice (57, 72).

CYP7A1 catalyzes the rate-limiting step in bile synthesis, a major consumer of cholesterol; downregulation of CYP7A1 lowers cholesterol catabolism, raising cholesterol levels (60). Both FASD and the Mthfr<sup>−/−</sup> genotype significantly lowered Cyp7a1 expression. Greater methylation of Cyp7a1 CpGs in Mthfr<sup>−/−</sup> mice may have contributed to this effect. Reduced CYP7A1 may result in a buildup of intracellular cholesterol, leading to toxic effects such as altered membrane integrity; reduced CYP7A1 is associated with greater severity of NASH (56).

Altered lipid gene expression, activation of SREBP-1, and disturbed PtdCho metabolism suggest that lipid accumulation may be involved in the hepatocyte degeneration in FASD Mthfr<sup>−/−</sup> mice. The heavier livers are consistent with lipid accumulation as in other models (for review, see da Silva et al. (51)) and enlargement of degenerating cells. Liver greater weights correlated with the presence of widespread degenerating hepatocytes (Pearson correlation r = 0.502, 2-tailed P = 0.006). FASD also induced a proapoptotic environment, which may predispose FASD Mthfr<sup>−/−</sup> hepatocytes to enter apoptosis in response to injury.

FASD may cause epigenetic changes due to reduced SAM and aberrant DNA methylation that could affect health [reviewed in Smith (4)]. MTHFR deficiency in humans and mice is associated with altered DNA methylation (32, 73). Methylation changes could influence expression of a variety of genes. We observed greater methylation of 2 CpGs in Cyp7a1 that could contribute to its reduced expression in Mthfr<sup>−/−</sup> mice. Similarly, Devlin et al. (58) reported greater methylation in Fads2 associated with reduced Fads2 mRNA in mice fed a low-folate, high-methionine diet.

In conclusion, high folic acid consumption in mice results in a state of MTHFR deficiency, with reduced methylTHF and methylation capacity. Findings in murine studies may not be directly extrapolated to the human situation, but they suggest that additional studies are warranted, given the increased folate intake in many populations. Many of the dramatic effects on choline metabolites and gene expression were due to the combination of MTHFR deficiency and FASD. These findings suggest a 2-hit mechanism whereby MTHFR-deficient hepatocytes are less able to mitigate the effect of phospholipid and lipid disturbances, leading to hepatocyte injury. MTHFR deficiency in hepatocytes may set the stage for other insults (e.g., high-fat diets) that could also lead to NAFLD. Further study is necessary because the small sample size may be insufficient to detect important genotype-diet interactions, and the lack of correction for multiple testing in this preliminary report raises the possibility of type I error. Nonetheless, these results may have implications for the human population, as genotype-diet interactions are known to modulate disease risk in MTHFR 677 C>T individuals (31). It may be important to consider variation in folate-related genes when making recommendations for folic acid intake at both the high and low ends of the dietary folate spectrum.

We thank Daniel Leclerc for the design of the Nr1h4 quantitative RT-PCR primers, pointing out a differentially methylated DNA region in Cyp7a1, and the design of the pyrosequencing primers.

The authors’ responsibilities were as follows—KEC, LGM, and RR: designed the research; KEC, LGM, K-YL, NL, LD, QW, OVM, MAC, and NDEG: conducted the research; KEC, LGM, and AB: performed the statistical analysis of data; KEC and RR: wrote the manuscript; and RR: had primary responsibility for final content. All authors read and approved the final manuscript and reported no conflicts of interest.

REFERENCES
1. De Wals P, Tairou F, Van Allen MI, Uh SH, Lowry RB, Sibbald B, Evans JA, Van den Hof MC, Zimmer P, Crowley M, et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007;357:135–42.
HIGH FOLIC ACID INTAKE, MTHFR, AND LIVER INJURY

Boulet SL, Yang Q, Mai C, Kirby RS, Collins JS, Robbins JM, Meyer R, Canfield MA, Mulinarie J. Trends in the postinfection prevalence of spina bifida and anencephaly in the United States. Birth Defects Res A Clin Mol Teratol 2008;82:527–32.

Ionescu-Itoiu R, Marelli AS, Pilote L. Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada. BMJ 2009;338:b1673.

Smith AD, Kim YI, Refsum H. Is folic acid good for everyone? Am J Clin Nutr 2008;7:517–33.

Crider KS, Bailey LB, Berry RJ. Folic acid food fortification—its history, effect, concerns, and future directions. Nutrients 2011;3:570–84.

Bailey RL, Dodd KW, Gaheche JJ, Dwyer JT, McDowell MA, Yetley EA, Sempos CA, Burt VL, Radimer KL, Picciano MF. Total folate and folic acid intake from foods and dietary supplements in the United States: 2003–2006. Am J Clin Nutr 2010;91:231–7.

Bailey RL, McDowell MA, Dodd KW, Gaheche JJ, Dwyer JT, Picciano MF. Total folate and folic acid intake from foods and dietary supplements of US children aged 1–13 y. Am J Clin Nutr 2010;92:553–8.

Yeung LF, Cogswell ME, Carriquiry AL, Bailey LB, Pfeiffer CM, Crider KS, Bailey LB, Berry RJ. Folic acid food fortification—its history, effect, concerns, and future directions. Nutrients 2011;3:570–84.

Bailey RL, Dodd KW, Gaheche JJ, Dwyer JT, McDowell MA, Yetley EA, Sempos CA, Burt VL, Radimer KL, Picciano MF. Total folate and folic acid intake from foods and dietary supplements in the United States: 2003–2006. Am J Clin Nutr 2010;91:231–7.

Bailey RL, McDowell MA, Dodd KW, Gaheche JJ, Dwyer JT, Picciano MF. Total folate and folic acid intake from foods and dietary supplements of US children aged 1–13 y. Am J Clin Nutr 2010;92:553–8.

Yeung LF, Cogswell ME, Carriquiry AL, Bailey LB, Pfeiffer CM, Crider KS, Bailey LB, Berry RJ. Folic acid food fortification—its history, effect, concerns, and future directions. Nutrients 2011;3:570–84.

Wilson RD, Johnson JA, Wyatt P, Allen V, Gagnon A, Langlois S, Centers for Disease Control (CDC). Use of folic acid for prevention of neural tube defects—1989–1996. MMWR Morb Mortal Wkly Rep 1997;46:685–9.

Kalmbach RD, Choumenkovitch SF, Troen AM, D’Agostino R, Jacques PF, Rosenberg IH, Selhub J. Circulating un-metabolized folic acid and 5-methyltetrahydrofolate in relation to folic acid fortification. Am J Clin Nutr 2008;88:763–8.

Centers for Disease Control (CDC). Use of folic acid for prevention of spina bifida and other neural tube defects—1983–1991. MMWR Morb Mortal Wkly Rep 1991;40:513–6.

Wilson RD, Johnson JA, Wyatt P, Allen V, Gagnon A, Langlois S, Centers for Disease Control (CDC). Use of folic acid for prevention of neural tube defects—1989–1996. MMWR Morb Mortal Wkly Rep 1997;46:685–9.

Kalmbach RD, Choumenkovitch SF, Troen AM, D’Agostino R, Jacques PF, Rosenberg IH, Selhub J. Circulating un-metabolized folic acid and 5-methyltetrahydrofolate in relation to folic acid fortification. Am J Clin Nutr 2008;88:763–8.

Centers for Disease Control (CDC). Use of folic acid for prevention of spina bifida and other neural tube defects—1983–1991. MMWR Morb Mortal Wkly Rep 1991;40:513–6.

Koc H, Mar MH, Ranasinghe A, Swenberg JA, Zeisel SH. Quantitation of 5,10-methylenetetrahydrofolate reductase activity by S-adenosylmethionine and by dihydrofolate and its polyglutamate analogues. Adv Enzyme Regul 1982;20:123–5.

Allegre CJ, Drake JC, Jolivet J, Chabran BA. Inhibition of phosphoribosylaminomimidazolecarboxamide transformylase by methotrexate and dihydrofolate polyglutamates. Proc Natl Acad Sci USA 1985;82:4881–5.

Sunder SN, Renduchintala MS, Park EIL, Miklasz SD, Garrow TA. Betaine-homocysteine methyltransferase expression in porcine and human tissues and chromosomal localization of the human gene. Arch Biochem Biophys 1997;345:171–4.

Schwahn BC, Chen Z, Laryea MD, Wendel U, Lussier-Cacan S, Genest JJ, Mar-H, Zeisel SH, Castro C, Garrow T, et al. Homocysteine betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. FASEB J 2003;17:512–4.

Jan Y, Wang W, Gregory JF 3rd, Malysheva O, Brenna JT, Stabler SP, Allen RH, Caudill MA. MTHFR C677T genotype influences the isotope enrichment of one-carbon metabolites in folate-compromised men consuming d9-choline. Am J Clin Nutr 2011;93:348–55.

Christensen KE, Rozen D, Reznik H. Genetic variation: effect on folate metabolism and health. In: Bailey LB, editor. Folate in health and disease. 2nd ed. Boca Raton (FL): CRC Press; 2010. p. 75–110.

Zenz C, Karapalis AC, Ackerman SL, Pogribny IP, Melynky S, Lussier-Cacan S, Chen MF, Pai A, John SW, Smith RS, et al. Mouse deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylhyation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001;10:433–43.

Idrees PG. Components of the AIN-93 diets as improvements in the AIN-76A diet. J Nutr 1997;127:838S–418.

Goyette P, Christensen B, Rosenblatt DS, Rozen R. Severe and mild mutations in cis for the methylenetetrahydrofolate reductase (MTHFR) gene, and description of five novel mutations in MTHFR. Am J Hum Genet 1996;59:1268–75.

Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Khutrimans LA, van den Heuvel LP, et al. Candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–3.

Yamada K, Strahler JR, Andrews PC, Matthews RG. Regulation of human methylenetetrahydrofolate reductase by phosphorylation. Proc Natl Acad Sci USA 2005;102:10454–9.

Christensen KE, Deng L, Leung KY, Arning E, Bottiglieri T, Malysheva OV, Caudill MA, Krupenko NI, Greene ND, Jerome-Majewksa L, et al. A novel mouse model for genetic variation in 10-formyltetrahydrofolate synthetase exhibits disturbed purine synthesis with impacts on pregnancy and embryonic development. Hum Mol Genet 2013;22:3705–19.

Cabeiro F, Au C, Leung KY, Vergara-Irigaray N, Cocheme HM, Noori Mort M, Choumenkovitch SF, Rozen R, Leung KY, Arning E, et al. Folate and MTHFR genotype influence choline status in young Mexican American women. J Nutr Biochem 2008;19:158–65.
42. Kim JK, Harada K, Bamba T, Fukusaki E, Kobayashi A. Stable isotope dilution-based accurate comparative quantification of nitrogen-containing metabolites in Arabidopsis thaliana T87 cells using in vivo (15N-isotope enrichment. Biocatal Biotechnol Biochem 2005;69:1331–40.

43. Jiang X, Yan J, West AA, Perry CA, Malyshova OV, Devapalat S, Pressman E, Vermylen F, Caudill MA. Maternal choline intake alters the epigenetic state of fetal cortisol-regulating genes in humans. FASEB J 2012;26:3563–74.

44. Knock E, Deng L, Wu Q, Leclerc D, Wang XL, Rozen R. Low dietary folate initiates intestinal tumors in mice, with altered expression of G2-M checkpoint regulators polo-like kinase 1 and cell division cycle 25c. Cancer Res 2006;66:10349–56.

45. Leclerc D, Cao Y, Deng L, Mikael LG, Wu Q, Rozen R. Differential gene expression and methylation in the retinoid/PPARα pathway and of tumor suppressors may modify intestinal tumorigenesis induced by low folate in mice. Mol Nutr Food Res 2013;57:686–97.

46. Vandensempele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepel A, Speelman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.

47. Garcia-Crespo D, Knock E, Jabado N, Rozen R. Betaine supplementation improves the atherogenic risk factor profile in a transgenic mouse model of hyperhomocysteinemia. J Lipid Res 2011;52:277–83.

48. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 2012;13:134.

49. Irazary RA, Ladd-Acosta C, Wen B, Li Z, Bailey LB, et al. MTHFR 677C>T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation. Am J Clin Nutr 2011;93:1365–72.

50. Pfeiffer CM, Hughes JP, Lackier DA, Bailey RL, Berry RJ, Zhang M, Yetley EA, Rader JH, Sembros CT, Johnson CL. Estimation of trends in serum and RBC folate in the U.S. population from pre- to post-fortification using assay-adjusted data from the NHANES 1988–2010. J Nutr 2012;142:886–93.

51. Kalhan SC, Edmison J, Marczewski S, Dasarathy S, Grucha LL, Bennett C, Duenas C, Lopez R. Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. Clin Sci (Lond) 2011;121:179–89.

52. Fast DG, Vance DE. Nascent VLDL phospholipid composition is altered when phosphatidylcholine biosynthesis is inhibited: evidence for a novel mechanism that regulates VLDL secretion. Biochim Biophys Acta 1995;1258:159–69.

53. Cano A, Buque X, Martinez-Unia M, Aurrekoetxea I, Menor A, Garcia-Rodriguez JL, Lu SC, Martinez-Chantar ML, Mato JM, Ochoa B, et al. Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice. Hepatology 2011;54:1975–86.

54. Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, Vance DE. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 2006;3:321–31.

55. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator–activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003;17:259–72.

56. Haemmerle G, Moustafa T, Woelkart G, Buttner S, Schmidt A, van de Meerakker K, Bak. Endocrinology 2006;147:4960–7.

57. Higgins ME, Ioannou YA. Apoptosis-induced release of mature sterol regulatory element-binding proteins activates sterol-responsive genes. J Biol Chem 2001;42:1939–46.

58. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, Malarkey DE, Kaufmann W, Kuttler K, Deschl U, et al. Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. Toxicol Pathol 2010;38:858–69.

59. da Silva RP, Kelly KB, Al Rajabi A, Jacobs RL. Novel insights on interactions between folate and lipid metabolism. Biofactors 2014;40:277–83.

60. Schwahn BC, Wang XL, Mikael LG, Wu Q, Cohn J, Jiang H, Maclean KN, Rozen R. Betaine supplementation improves the atherogenic risk factor profile in a transgenic mouse model of hyperhomocysteinemia. Atherosclerosis 2007;195:e100–7.

61. MacFarlane AJ, Behan NA, Matias FM, Green J, Caldwell D, Brooks SF. Dietary folate does not significantly affect the intestinal microbiome, inflammation or tumorigenesis in azoxymethane-dextran sodium sulphate-treated mice. Br J Nutr 2013;109:630–8.

62. Jacobs HP, Baumann CA, Meek WJ. The choline content of rats on various choline-free diets. J Biol Chem 1941;138:571–82.

63. Thoolen B, Maronpot RR, Harada T, Ntambi JM. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab 2007;6:484–96.

64. Modica S, Gadala RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal 2010;8:e005.

65. Wang AK, Jacobs RL, Watts JL, Rottiers V, Jiang K, Finnegan DM, Shiota T, Hansen M, Yang F, Niebergall LJ, et al. A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell 2011;147:840–52.

66. Castilla C, Congregado B, Chinchon D, Torrubia FJ, Japon MA, Saez C. Betaine is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 2006;147:4960–7.

67. Garcia-Crespo D, Knock E, Jabado N, Rozen R. Intestinal neoplasia induced by low dietary folate is associated with altered tumor expression profiles and decreased apoptosis in mouse normal intestine. J Nutr 2000;130:988–94.

68. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 2012;13:134.

69. Jha P, Claudel T, Baghdasaryan A, Mueller M, Halilbasic E, Das SK, Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator–activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003;17:259–72.

70. Haemmerle G, Moustafa T, Woelkart G, Buttner S, Schmidt A, van de Meerakker K, Bak. Endocrinology 2006;147:4960–7.

71. Haemmerle G, Moustafa T, Woelkart G, Buttner S, Schmidt A, van de Meerakker K, Bak. Endocrinology 2006;147:4960–7.

72. Jha P, Claudel T, Baghdasaryan A, Mueller M, Halilbasic E, Das SK, Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator–activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003;17:259–72.

73. Heemskerk S, Kooistra J, Schipperissen JG, Zwart J, van der Post JC, van der Veen M. Expression profiles and decreased apoptosis in mouse normal intestine. J Biol Chem 2012;287:37082–90.

74. Miyazaki M, Flowers MT, Sampath H, Chu K, Otselberger C, Liu X, Ntambi JM. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab 2007;6:484–96.

75. Modica S, Gadala RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal 2010;8:e005.

76. Walker AK, Jacobs RL, Watts JL, Rottiers V, Jiang K, Finnegan DM, Shiota T, Hansen M, Yang F, Niebergall LJ, et al. A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell 2011;147:840–52.

77. Cresta C, Congregado B, Chinchon D, Torrubia FJ, Japon MA, Saez C. Betaine is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 2006;147:4960–7.